A Phase 3 Multicenter, Multinational, Randomized, Double- blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Study for patients with Amyloidsis (TTR) using an investigational drug, ALN-TTR02 for treatment
Sponsor: Alnylam Pharmaceuticals
Enrolling: Male and Female Patients
Study Length: 18 Months
IRB Number: AAAM4504
U.S. Govt. ID: NCT01960348
Contact: Jacqueline Scoon: 212 305 6035 / js4462@cumc.columbia.edu
Additional Study Information: The purpose of this study is to collect information about how patients with FAP respond to the study drug ALN-TTR02 over 18 months. This includes studying any potential improvements in FAP and any side effects that participants may have from the study drug. In addition, the study will examine how the body handles (distributes, break down, eliminates) the study drug by measuring the amount of drug that gets into blood and urine after dosing.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Have you been diagnosed with FAP? Yes No
Have you had a liver transplant or are planning to undergo a liver transplant soon? Yes No
Have you recently received an investigational agent or device? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jacqueline Scoon
212 305 6035